Literature DB >> 22225523

Liver transplantation for hepatitis C from donation after cardiac death donors: an analysis of OPTN/UNOS data.

T Uemura1, V Ramprasad, C S Hollenbeak, D Bezinover, Z Kadry.   

Abstract

Donation after cardiac death (DCD) liver transplantation is increasing largely because of a shortage of organs. However, there are almost no data that have specifically assessed the impact of using DCD livers for HCV patients. We retrospectively studied adult primary DCD liver transplantation (630 HCV, 1164 non-HCV) and 54 129 donation after brain death (DBD) liver transplantation between 2002 and 2009 using the UNOS/OPTN database. With donation after brain death (DBD) livers, HCV recipients had significantly inferior graft survival compared to non-HCV recipients (p < 0.0001). Contrary to DBD donors, DCD livers used in HCV patients showed no difference in graft survival compared to non-HCV patients (p = 0.5170). Cox models showed DCD livers and HCV disease had poorer graft survival (HR = 1.80 and 1.28, p < 0.0001, respectively). However, the hazard ratio of DCD and HCV interaction was 0.80 (p = 0.02) and these results suggest that DCD livers on HCV disease do not fare worse than DCD livers on non-HCV disease. The graft survival of recent years (2006-2009) was significantly better than that in former years (2002-2005) (p = 0.0482). In conclusion, DCD liver transplantation for HCV disease showed satisfactory outcomes. DCD liver transplantation can be valuable option for HCV related end-stage liver disease. © Copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2012        PMID: 22225523     DOI: 10.1111/j.1600-6143.2011.03899.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  9 in total

Review 1.  Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.

Authors:  Maria Kalafateli; Elena Buzzetti; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-13

2.  Live liver donors' risk thresholds: risking a life to save a life.

Authors:  Michele Molinari; Jacob Matz; Sarah DeCoutere; Karim El-Tawil; Bassam Abu-Wasel; Valerie Keough
Journal:  HPB (Oxford)       Date:  2013-11-20       Impact factor: 3.647

Review 3.  Comparing outcomes of donation after cardiac death versus donation after brain death in liver transplant recipients with hepatitis C: a systematic review and meta-analysis.

Authors:  Malcolm Wells; Kris M Croome; Toni Janik; Roberto M Hernandez-Alejandro; Natasha M Chandok
Journal:  Can J Gastroenterol Hepatol       Date:  2013-11-28

4.  Donation after cardio-circulatory death liver transplantation.

Authors:  Hieu Le Dinh; Arnaud de Roover; Abdour Kaba; Séverine Lauwick; Jean Joris; Jean Delwaide; Pierre Honoré; Michel Meurisse; Olivier Detry
Journal:  World J Gastroenterol       Date:  2012-09-07       Impact factor: 5.742

5.  Liver transplantation and hepatitis C.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara
Journal:  Int J Hepatol       Date:  2012-07-26

6.  Pharmacological interventions for acute hepatitis C infection.

Authors:  Maria Kalafateli; Elena Buzzetti; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2018-12-03

Review 7.  Hepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and Management.

Authors:  Bobby Kakati; Anil Seetharam
Journal:  J Clin Transl Hepatol       Date:  2014-09-15

8.  Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review.

Authors:  Malcolm M Wells; Lee S Roth; Paul Marotta; Mark Levstik; Andrew L Mason; Vincent G Bain; Natasha Chandok; Bandar M Aljudaibi
Journal:  Saudi J Gastroenterol       Date:  2013 Sep-Oct       Impact factor: 2.485

Review 9.  The new era of hepatitis C virus therapy.

Authors:  Bandar Al-Judaibi
Journal:  Saudi J Gastroenterol       Date:  2015 Nov-Dec       Impact factor: 2.485

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.